Yes, that's the one. Thank you Ohm. Looks li
Post# of 155430
(Total Views: 435)
Posted On: 07/02/2021 1:13:51 PM
Yes, that's the one. Thank you Ohm.
Looks like it is still an active application, just published on June 10, 2021. https://patents.justia.com/patent/20210171646#history
From the excerpts below, it would appear that this patent not only relies on but specifically includes the MOA of Leronlimab and IP of Cytodyn:
"55. The method according to any of claims 36 to 54, the method further comprising treating the subject having a critical or severe form of the disease by administering to the subject a CCR5/CCL5 interaction inhibitor.
56. The method according to claim 55, wherein the CRL5/CCL5 interaction inhibitor is a CCR5 antagonist.
57. The method according to claim 56, wherein the CCR5 antagonist is a specific binding member for CCR5.
58. The method according to claim 57, wherein the specific binding member for CCR5 is an antibody that specifically binds to CCR5.
59. The method according to claim 58, wherein the antibody that specifically binds to CCR5 is a humanized monoclonal antibody.
60. The method according to claim 59, wherein the antibody that specifically binds to CCR5 is Leronlimab (PRO 140).
61. The method according to claim 56, wherein the CCR5 antagonist is a small molecule.
* * *
83. The method according to any of claims 64 to 82, the method further comprising treating the subject having a critical or severe form of the disease by administering to the subject a CCR5/CCL5 interaction inhibitor.
84. The method according to claim 83, wherein the CCR5/CCL5 interaction inhibitor is a CCR5 antagonist.
85. The method according to claim 84, wherein the CCR5 antagonist is a specific binding member for CCR5.
86. The method according to claim 85, wherein the specific binding member for CCR5 is an antibody that specifically binds to CCR5.
87. The method according to claim 86, wherein the antibody that specifically binds to CCR5 is a humanized monoclonal antibody.
88. The method according to claim 87, wherein the antibody that specifically binds to CCR5 is Leronlimab (PRO 140)."
Is it any wonder there was a falling out between CYDY and Patterson? This is a gross over-reach by Patterson and if it wasn't authored by him, it should have been caught and remedied right away. No excuse to use CYDY intellectual property without including them in the patent.
Looks like it is still an active application, just published on June 10, 2021. https://patents.justia.com/patent/20210171646#history
From the excerpts below, it would appear that this patent not only relies on but specifically includes the MOA of Leronlimab and IP of Cytodyn:
"55. The method according to any of claims 36 to 54, the method further comprising treating the subject having a critical or severe form of the disease by administering to the subject a CCR5/CCL5 interaction inhibitor.
56. The method according to claim 55, wherein the CRL5/CCL5 interaction inhibitor is a CCR5 antagonist.
57. The method according to claim 56, wherein the CCR5 antagonist is a specific binding member for CCR5.
58. The method according to claim 57, wherein the specific binding member for CCR5 is an antibody that specifically binds to CCR5.
59. The method according to claim 58, wherein the antibody that specifically binds to CCR5 is a humanized monoclonal antibody.
60. The method according to claim 59, wherein the antibody that specifically binds to CCR5 is Leronlimab (PRO 140).
61. The method according to claim 56, wherein the CCR5 antagonist is a small molecule.
* * *
83. The method according to any of claims 64 to 82, the method further comprising treating the subject having a critical or severe form of the disease by administering to the subject a CCR5/CCL5 interaction inhibitor.
84. The method according to claim 83, wherein the CCR5/CCL5 interaction inhibitor is a CCR5 antagonist.
85. The method according to claim 84, wherein the CCR5 antagonist is a specific binding member for CCR5.
86. The method according to claim 85, wherein the specific binding member for CCR5 is an antibody that specifically binds to CCR5.
87. The method according to claim 86, wherein the antibody that specifically binds to CCR5 is a humanized monoclonal antibody.
88. The method according to claim 87, wherein the antibody that specifically binds to CCR5 is Leronlimab (PRO 140)."
Is it any wonder there was a falling out between CYDY and Patterson? This is a gross over-reach by Patterson and if it wasn't authored by him, it should have been caught and remedied right away. No excuse to use CYDY intellectual property without including them in the patent.
(10)
(0)